RxDoctor Payments Data

John Elliott, MD

Internal Medicine · Atlanta, GANPI 1174942171

Payments from drug & device makers

$510in general payments, 2019–2025

Across 36 payments — averaging $14.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$401
  • Kvk-tech, Inc.$30
  • Gilead$28
  • GSK$19
  • Pfizer$18
  • Johnson & Johnson$14

What the payments were for

  • Food & beverage$510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company30$401
Kvk-tech, Inc.2$30
Gilead1$28
GSK1$19
Pfizer1$18
Johnson & Johnson1$14

How this compares

$510 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$55,038
Medicare patients
124
Services billed
968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine129$440,120
BiktarvyBictegrav/Emtricit/Tenofov Ala77$338,180
JulucaDolutegravir/Rilpivirine62$251,781
OdefseyEmtricitab/Rilpiviri/Tenof Ala35$144,144
TriumeqAbacavir/Dolutegravir/Lamivudi22$115,562
PrezcobixDarunavir/Cobicistat32$105,812
TivicayDolutegravir Sodium20$61,522
FarxigaDapagliflozin Propanediol25$42,116
IsentressRaltegravir Potassium13$40,395
OzempicSemaglutide24$31,460
JanuviaSitagliptin Phosphate19$29,717
DescovyEmtricitabine/Tenofov Alafenam12$25,697
ArexvyRsvpref3 Antigen/As01e/Pf41$12,579
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)21$9,947
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca, Triumeq, Tivicay$401$868,985233 claims
GileadBiktarvy, Descovy$28$363,87789 claims
Johnson & JohnsonPrezcobix$14$105,81232 claims
GSKArexvy$19$12,57941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →